Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in viv

Authors

Hibiki Kawamata, Weill Cornell Medical College
Pablo Peixoto, CUNY Bernard M Baruch CollegeFollow
Csaba Konrad, Weill Cornell Medical College
Gloria Palomo, Weill Cornell Medical College
Kirsten Bredvik, Weill Cornell Medical College
Meri Gerges, Weill Cornell Medical College
Federica Valsecchi, Weill Cornell Medical College
Leonard Petrucelli, Mayo Clinic
John M. Ravits, University of California - San Diego
Anatoly Starkov, Weill Cornell Medical College
Giovanni Manfredi, Weill Cornell Medical College

Document Type

Article

Publication Date

5-8-2017

Abstract

Background: Mitochondrial dysfunction has been linked to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Functional studies of mitochondrial bioenergetics have focused mostly on superoxide dismutase 1 (SOD1) mutants, and showed that mutant human SOD1 impairs mitochondrial oxidative phosphorylation, calcium homeostasis, and dynamics. However, recent reports have indicated that alterations in transactivation response element DNA-binding protein 43 (TDP-43) can also lead to defects of mitochondrial morphology and dynamics. Furthermore, it was proposed that TDP-43 mutations cause oxidative phosphorylation impairment associated with respiratory chain defects and that these effects were caused by mitochondrial localization of the mutant protein. Here, we investigated the presence of bioenergetic defects in the brain of transgenic mice expressing human mutant TDP-43 (TDP-43A315T mice), patient derived fibroblasts, and human cells expressing mutant forms of TDP-43.

Methods: In the brain of TDP-43A315T mice, TDP-43 mutant fibroblasts, and cells expressing mutant TDP-43, we tested several bioenergetics parameters, including mitochondrial respiration, ATP synthesis, and calcium handling. Differences between mutant and control samples were evaluated by student t-test or by ANOVA, followed by Bonferroni correction, when more than two groups were compared. Mitochondrial localization of TDP-43 was investigated by immunocytochemistry in fibroblasts and by subcellular fractionation and western blot of mitochondrial fractions in mouse brain.

Results: We did not observe defects in any of the mitochondrial bioenergetic functions that were tested in TDP-43 mutants. We detected a small amount of TDP-43A315T peripherally associated with brain mitochondria. However, there was no correlation between TDP-43 associated with mitochondria and respiratory chain dysfunction. In addition, we observed increased calcium uptake in mitochondria from TDP-43A315T mouse brain and cells expressing A315T mutant TDP-43.

Conclusions: While alterations of mitochondrial morphology and dynamics in TDP-43 mutant neurons are well established, the present study did not demonstrate oxidative phosphorylation defects in TDP-43 mutants, in vitro and in vivo. On the other hand, the increase in mitochondrial calcium uptake in A315T TDP-43 mutants was an intriguing finding, which needs to be investigated further to understand its mechanisms and potential pathogenic implications.

Comments

This article was originally published in Molecular Neurodegeneration, available at DOI 10.1186/s13024-017-0180-1.

This article was published under the terms of the Creative Commons Attribution 4.0 International License.